CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein

Vaccine

Volumn 21, Issue 1-2, 2002, Pages 127-137

  Ioannou, X P ^a   Gomis, S M ^a   Karvonen, B ^a   Hecker, R ^b   Babiuk, L A ^a   Van Drunen Littel Van Den Hurk, S ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b QIAGEN GMBH   (Germany)

Author keywords

Adjuvant; CpG ODN; Immunization; Vaccination

Indexed keywords

ADJUVANT; FREUND ADJUVANT; GAMMA INTERFERON; GLYCOPROTEIN; HERPES VACCINE; IMMUNOGLOBULIN G; INTERLEUKIN 4; MINERAL OIL; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PLACEBO; BOVINE HERPESVIRUS TYPE 1 GLYCOPROTEINS; BOVINE HERPESVIRUS TYPE-1 GLYCOPROTEINS; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; RECOMBINANT VACCINE; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATTLE; CONTROLLED STUDY; FEMALE; HERPES; HERPES VIRUS; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHEEP; SPLEEN CELL; TH1 CELL; TH2 CELL; TISSUE INJURY; ANIMAL; ANIMAL DISEASE; BAGG ALBINO MOUSE; BIOSYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HERPES VIRUS INFECTION; IMMUNIZATION; IMMUNOLOGY; INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, BOVINE; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; SHEEP; TH1 CELLS; TH2 CELLS; VACCINES, SYNTHETIC; VIRAL PROTEINS; VIRAL VACCINES;

EID: 0037159625     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00378-X     Document Type: Article

References (51)

1. Cox J.C., Coulter A.R. Adjuvants - a classification and review of their modes of action. Vaccine. 15:1997;248-256.
2. Bomford R. Will adjuvants be needed for vaccines of the future. Dev. Biol. Stand. 92:1998;13-17.
3. Brazolot Millan C.L., Weeratna R.D., Krieg A.M., Siegrist C.A., Davis H.L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. U.S.A. 95:1998;15553-15558.
4. Davis H.L., Weeratna R.D., Waldschmidt M., Tygrett L., Schorr J., Krieg A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:1998;870-876.
5. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32:1998;155-172.
6. Klinman D.M., Barnhart K.M., Conover J. CpG motifs as immune adjuvants. Vaccine. 17:1999;19-25.
7. Kline J.N., Waldschmidt T.J., Businga T.R.et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160:1998;2555-2559.
8. Kline J.N. Effects of CpG DNA on Th1/Th2 balance in asthma. Curr. Top. Microbiol. Immunol. 247:2000;211-225.
9. Chisari F.V., Ferrari C. Hepatitis B virus immunpathogenesis. Annu. Rev. Immunol. 13:1995;29-60.
10. Heinzel F.P., Sadick M.D., Holaday B.J., Coffman R.L., Locksley R.M. Reciprocal expression of interferon-γ or interleukin-4 during the resolution or progression of murine leishmaniasis. Evidence of expansion of distinct helper T cell subsets. J. Exp. Med. 169:1998;59-72.
11. Sher A., Coffman R.L. Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu. Rev. Immunol. 10:1992;385-409.
12. Sher A. Schistosomiasis. Parasitizing the cytokine system. Nature. 16:1992;565-566.
13. Heeg K., Zimmermann S. CpG DNA as a Th1 trigger. Int. Arch. Allergy Immunol. 121:2000;87-97.
14. Kline J.N. Effects of CpG DNA on Th1/Th2 balance in asthma. Curr. Top. Microbiol. Immunol. 247:2000;211-225.
15. Rankin R., Pontarollo R., Gomis S.M.et al. CpG containing oligodeoxynucleotides augment and switch immune responses of cattle to bovine herpesvirus-1. Vaccine. 20:2002;3014-3022.
16. Gibbs EPJ, Rweyemamu MM. Bovine herpesvirus-1. In: Bovine Herpesvirus. Vet Bull (London) 1977;47:317-43.
17. Yates W.D.G. A review of infectious bovine rhinotracheitis, shipping fever pneumonia and viral-bacterial synergism in respiratory disease of cattle. Can. J. Comp. Med. 46:1982;225-263.
18. van Drunen Littel-van den Hurk S., Van Donkersgoed J., Kowalski J. A subunit gIV vaccine, produced by transfected mammalian cells in culture, induces mucosal immunity against bovine herpesvirus-1 in cattle. Vaccine. 12:1994;1295-1302.
19. Leenaars M., Koedam M.A., Hendriksen C.F., Claassen E. Immune responses and side effects of five different oil-based adjuvants in mice. Vet. Immunol. Immunopathol. 61:1998;291-304.
20. Fukanoki S., Matsumoto K., Mori H., Takeda R. Effect of liquid paraffin on antibody response and local adverse reactions of bivalent oil adjuvanted vaccines containing Newcastle disease virus and infectious bronchitis virus. J. Vet. Med. Sci. 62:2000;1317-1319.
21. Straw B.E., MacLachlan N.J., Corbett W.T., Carter P.B., Schey H.M. Comparison of tissue site reactions produced by Haemophilus pleuropneumoniae vaccines made with six different adjuvants in mice. Can. J. Comp. Med. 49:1985;149-151.
22. Migliore-Samour D., Floc'h F., Maral R., Werner G.H., Jolles P. Adjuvant activities of chemically modified water-soluble substances from Mycobacterium turberculosis. Immunology. 33:1977;477-484.
23. Lofthouse S.A., Andrews A.E., Nash A.D., Bowles V.M. Humoral and cellular responses induced by intradermally administered cytokine and conventional adjuvants. Vaccine. 13:1995;1131-1137.
24. Willson P.J., Rossi-Campos A., Potter A.A. Tissue reaction and immunity in swine immunized with Actinobacillus pleuropneumoniae vaccines. Can. J. Vet. Res. 59:1995;299-305.
25. Weeratna R.D., McCluskie M.J., Xu Y., Davis H.L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine. 18:2000;1755-1762.
26. Davis HL, Cooper CL, Morris ML, Efler SM, Cameron DW, Heathcote J. CpG ODN is safe and highly effective in humans as adjuvant to HBV vaccine. In: Proceedings of the Third Annual Conference on Vaccine Research, 2000. vol. S25. p. 47 [Abstract].
27. Davis HL, Krieg AM, Cooper CL, Morris ML, Cameron DW, Heathcote J. CpG ODN is generally well tolerated and highly effective in humans as adjuvant to HBV vaccine: Preliminary results of phase 1 trial with CpG ODN 7909. In: Activating immunity with CpG oligos. Proceedings of the Second International Symposium, Amelia island, FL, 2001 [Abstract].
28. Kowalski J., Gilbert S.A., van Drunen Littel-van den Hurk S., Babiuk L.A., Zamb T.J. Heat-shock promoter-driven synthesis of secreted bovine herpesvirus glycoproteins in transfected cells. Vaccine. 11:1993;1100-1107.
29. van Drunen Littel-van den Hurk S., Gifford G.A., Babiuk L.A. Epitope specificity of the protective immune response induced by individual bovine herpesvirus-1 glycoproteins. Vaccine. 8:1990;358-368.
30. Rankin R., Pontarollo R., Ioannou X.et al. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid. Drug Dev. 11:2001;333-340.
31. Samani T.D., Jolles B., Laigle A. Best minimally modified antisense oligonucleotides according to cell nuclease activity. Antisense Nucleic Acid Drug Dev. 11:2001;129-136.
32. Lewis P.J., van Drunen Littel-van den Hurk S., Babiuk L.A. Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response. J. Virol. 73:1999;10214-10223.
33. Baca-Estrada M.E., Snider M., Tikoo S.K., Harland R., Babiuk L.A., van Drunen Littel-van den Hurk S. Immunogenicity of bovine herpesvirus-1 glycoprotein D in mice: effect of antigen form on the induction of cellular and humoral immune responses. Viral Immunol. 9:1996;11-22.
34. Raggo C., Habermehl M., Babiuk L.A., Griebel P. The in vivo effects of recombinant bovine herpesvirus-1 expressing bovine interferon-γ J. Gen. Virol. 81:2000;2665-2673.
35. Fresno M., Kopf M., Rivas L. Cytokines and infectious disease. Immunol. Today. 18:1997;56-58.
36. Ulmer J.B., Deck R.R., DeWitt C.M., Donnelly J.J., Liu M.A. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology. 89:1996;59-67.
37. Mosmann T.R., Coffman R.L. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:1989;145-173.
38. Roman M., Martin-Orozco E., Goodman J.S.et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3:1997;849-854.
39. Coutelier J.P., van der Logt T.M., Heessen W.A. IgG subclass distribution of primary and secondary immune responses concomitant with viral infection. J. Immunol. 147:1991;1383-1386.
40. Coutelier J.P., van der Logt T.M., Heessen W.A., Vink A., Van Snick J. Virally induced modulation of murine IgG antibody subclasses. J. Exp. Med. 168:1988;2373-2378.
41. Snapper C.M., Paul W.E. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science. 236:1987;944-947.
42. Bomford R. Aluminium salts: Perspectives in their use as adjuvants. In: Gregoriadis G, Allison AC, Poste G, editors. Immunological adjuvants and vaccines. New York: Plenum Press; 1989. p. 35-41.
43. Gupta R.K., Siber G.R. Comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid. Biologicals. 22:1994;53-63.
44. Levine L., Ipsen J., McComb J.A. Adult immunization: preparation and evaluation of combined fluid tetanus and diphtheria toxoids for adult use. Am. J. Hyg. 73:1961;20-35.
45. Levine L., McComb J.A., Dwyer R.C., Latham W.C. Active-passive tetenus immunization. New Eng. J. Med. 274:1966;186-190.
46. 3 as an immunological adjuvant. Acta Pathol. Microbiol. Immunol. Scand. 96:1988;257-264.
47. Livingston P. Ganglioside vaccines with emphasis on CM2. Semin. Oncol. 25:1998;638-645.
48. Musselli C., Livingston P.O., Ragupathi G. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience. J. Cancer Res. Clin. Oncol. 127:2001;R20-R26.
49. Waite D.C., Jacobson E.W., Ennis F.A.et al. Three double-blind randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine. 19:2001;3957-3967.
50. Gilewski T., Adluri S., Ragupathi G.et al. vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res. 6:2001;1693-1701.
51. Hamilton J.A., Byrne R.B., Whitty G. Particulate adjuvants can induce macrophage survival, DNA synthesis, and a synergistic proliferative response to GM-CSF and CSF-1. J. Leukoc. Biol. 67:2000;226-232.